Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pelthos Therapeutics Inc. Common Stock (NY:PTHS)

9.740 -0.410 (-4.04%)
Delayed Quote Updated: 12:58 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pelthos Therapeutics Inc. Common Stock

News headline image
Pelthos (PTHS) Q2 2026 Earnings Call Transcript ↗
ZELSUVMI revenue jumped 45% as prescriber count surged and new PBM contracts drove adoption. 
Via The Motley Fool
Topics Earnings
News headline image
Pelthos Therapeutics Q2 Earnings Call Highlights ↗
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment’s July 2025 commercial launch. The... 
Via MarketBeat
Topics Earnings
News headline image
Pelthos Therapeutics Q1 Earnings Call Highlights ↗
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch,... 
Via MarketBeat
Topics Earnings
Pelthos Therapeutics Inc (NYSEARCA:PTHS) Revenue Beats Estimates in Q1 2026, Net Loss Narrows ↗
Via Chartmill
Pelthos Therapeutics Inc. (PTHS) Reports Strong Q4 2025 Earnings Beat Amid Muted Market Reaction ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
News headline image
Pelthos Therapeutics Inc (NYSEARCA:PTHS) Stock Rises on Strong Q3 Revenue Beat ↗
Pelthos Therapeutics (PTHS) Q3 2025 results show a huge 66% revenue beat driven by strong demand for its new product ZELSUVMI, despite a significant EPS loss. 
Via Chartmill
News headline image
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch ↗
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts ↗
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones. 
Via Stocktwits
Topics Government
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease ↗
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.